LANTUS VS STANDARD CARE VS PLACEBO IN IFG, IGT AND EARLY TYPE II DIABETES MELLIT

$26,761M01FY2009RRNIH

Georgetown University, Washington DC

Investigators

Linked publications, trials & patents

Paper 38913861 Paper 38706462 Paper 38410951 Paper 38063529 Paper 37506298 Paper 36179266 Paper 35779438 Paper 35765986 Paper 35617264 Paper 35483500 Paper 35429700 Paper 34707329 Paper 34534914 Paper 34534857 Paper 34337570 Paper 34323265 Paper 33612145 Paper 33536949 Paper 33504263 Paper 33465008 Paper 32896862 Paper 32810694 Paper 32659693 Paper 32212770 Paper 31952925 Paper 31812102 Paper 31542635 Paper 31255951 Paper 31168579 Paper 31105380 Paper 31070400 Paper 30943214 Paper 30783672 Paper 30682500 Paper 30641284 Paper 30605796 Paper 30597101 Paper 30580073 Paper 30250240 Paper 29915079 Paper 29878042 Paper 29735350 Paper 29466893 Paper 29353512 Paper 29349266 Paper 29172602 Paper 29057014 Paper 29056783 Paper 28732236 Paper 28711699 Paper 28659244 Paper 28651371 Paper 28601752 Paper 28553813 Paper 28513316 Paper 28486177 Paper 28346146 Paper 28315111 Paper 28164150 Paper 27938923 Paper 27938909 Paper 27823815 Paper 27774807 Paper 27631613 Paper 27583527 Paper 27570892 Paper 27516421 Paper 27402684 Paper 27287937 Paper 27159187 Paper 26968206 Paper 26867082 Paper 26734956 Paper 26549645 Paper 26501729 Paper 26461246 Paper 26396508 Paper 26275377 Paper 26187318 Paper 26086344 Paper 26030309 Paper 25984827 Paper 25951236 Paper 25906914 Paper 25715901 Paper 25714703 Paper 25649677 Paper 25541185 Paper 25387699 Paper 25272201 Paper 25233337 Paper 24972822 Paper 24700968 Paper 24424630 Paper 24077742 Paper 23983216 Paper 23967186 Paper 23911591 Paper 23781017 Paper 23766379

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ORIGIN Study will evaluate whether people with IGT, IFG, and early type 2 diabetes who are at high risk for macrovascular events can be safely treated wih insulin glargine to near normal levels of blood glucose. It is hypothesized that this treatment will reduce their risk for future macrovascular and microvascular events compared to a control group who will be followed and treated according to normal guidelines.

View original record on NIH RePORTER →